Prognostic factors in metastatic prostate cancer
Authors:
Alžběta Kantorová; Viktor Soukup; Otakar Čapoun
Authors place of work:
Urologická klinika VFN a 1. LF UK, Praha
Published in the journal:
Ces Urol 2023; 27(2): 86-94
Category:
Review article
Summary
Metastatic prostate cancer (mPC) is a heterogeneous group of diseases with a median survival of 42 months. The basic treatment of mPC is always a combined treatment with androgen deprivation therapy (ADT – androgen deprivation therapy) with new antiandrogens (ARTA – androgen receptor targeted agents) such as enzalutamide, apalutamide, darolutamide or with the new testosterone synthesis blocker abiraterone acetate (AA) or with chemotherapy (docetaxel, cabazitaxel). To determine prognosis, we use prognostic factors that correlate with survival independent of systemic therapy. In this article, we provide an overview of the currently used prognostic factors.
Keywords:
prostate cancer – prognostic factors – metastatic prostate cancer – prognosis.
Zdroje
1. Scher HI. Observed Advantages of the STAMPEDE Study Design. Eur Urol. 2015; 67(6): 1039–41.
2. Romero Otero J, Garcia Gomez B, Campos Juanatey F, Touijer KA. Prostate cancer biomarkers: An update. Urol Oncol Semin Orig Investig. 2014; 32(3): 252– 60.
3. Veselý Š. Current clinical utility of prostate cancer markers. Onkologie. 2019; 13(2): 78–82.
4. Tang P, Sun L, Uhlman MA et al. Baseline PSA as a predictor of prostate cancer specific mortality over the past 2 decades: Duke University experience. Cancer. 2010; 116(20): 4711–7.
5. Řezáč J, Čapoun O, Soukup V. Serum oncomarkers for prostate cancer. Ces Urol. 2021; 25(4): 236–243.
6. Vickers AJ, Brewster SF. PSA Velocity and Doubling Time in Diagnosis and Prognosis of Prostate Cancer. Br J Med Surg Urol. 2012; 5(4): 162–8.
7. Hussain M, Tangen CM, Higano C, et al. Absolute Prostate‑Specific Antigen Value After Androgen Deprivation Is a Strong Independent Predictor of Survival in New Metastatic Prostate Cancer: Data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006; 24(24): 3984–90.
8. Lozar T, Gersak K, Cemazar M, Kuhar CG, Jesenko T. The biology and clinical potential of circulating tumor cells. Radiol Oncol. 2019; 53(2): 131–47.
9. Dathathri E, Isebia KT, Abali F, et al. Liquid Biopsy Based Circulating Biomarkers in Metastatic Prostate Cancer. Front Oncol. 2022; 12: 863472.
10. de Bono JS, Scher HI, Montgomery RB, et al. Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration‑Resistant Prostate Cancer. Clin Cancer Res. 2008; 14(19): 6302–9.
11. Scher HI, Heller G, Molina A, et al. Circulating Tumor Cell Biomarker Panel as an Individual‑Level Surrogate for Survival in Metastatic Castration‑Resistant Prostate Cancer. J Clin Oncol. 2015; 33(12): 348–55.
12. Vasseur A, Kiavue N, Bidard F, Pierga J, Cabel L. Clinical utility of circulating tumor cells: an update. Mol Oncol. 2021; 15(6): 1647–66.
13. Čapoun O, Soukup V, Mikulová V, et al. Cirkulující nádorové buňky a prognóza karcinomu prostaty. Čas. Lék. čes. 2014; 152: 72–77.
14. Petrelli F, Cabiddu M, Coinu A, et al. Prognostic role of lactate dehydrogenase in solid tumors: A systematic review and meta‑analysis of 76 studies. Acta Oncol. 2015; 54(7): 961–70.
15. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL. Lactate Dehydrogenase 5 Expression in Operable Colorectal Cancer: Strong Association with Survival and Activated Vascular Endothelial Growth Factor Pathway A Report of the Tumour Angiogenesis Research Group. J Clin Oncol. 2006; 24(26): 4301–8.
16. Li F, Xiang H, Pang Z, et al. Association between lactate dehydrogenase levels and oncologic outcomes in metastatic prostate cancer: A meta‑analysis. Cancer Med.2020; 9(19): 7341–51.
17. Epstein JI, Egevad L, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2016; 40(2): 244–52.
18. Karnofsky DA, Burchenal JH. Present status of clinical cancer chemotherapy. Am J Med. 1950; 8(6): 767–88.
19. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6): 649–55.
20. Kapoor R, Saxena AK, Vasudev P, Sundriyal D, Kumar A. Cancer induced bone pain: current management and future perspectives. Med Oncol. 2021; 38(11): 134.
21. Zajączkowska R, Kocot‑Kępska M, Leppert W, Wordliczek J. Bone Pain in Cancer Patients: Mechanisms and Current Treatment. Int J Mol Sci. 2019; 20(23): 6047.
22. Yoong J, Poon P. Principles of cancer pain management: An overview and focus on pharmacological and interventional strategies. Aust J Gen Pract. 2018; 47(11): 758–62.
23. Batson OV. The function of the vertebral veins and their role in the spread of metastases: Ann Surg. 1940; 112(1): 138–49.
24. Smith AE, Muralidharan A, Smith MT. Prostate cancer induced bone pain: pathobiology, current treatments and pain responses from recent clinical trials. Discov Oncol. 2022; 13(1): 108.
25. Yoneda T, Hiasa M, Nagata Y, Okui T, White FA. Acidic microenvironment and bone pain in cancer‑colonized bone. Bonekey Rep. 2015; 4: 690.
26. Halabi S, Vogelzang NJ, Kornblith AB, et al. Pain Predicts Overall Survival in Men with Metastatic Castration‑Refractory Prostate Cancer. J Clin Oncol. 2008; 26(15): 2544–9.
27. Jenšovský J. Sarkopenie: definice a diagnostika nové nemoci. Clin Osteol. 2019; 24(1): 14–18.
28. Cruz‑Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010; 39(4): 412–23.
29. Malmstrom TK, Morley JE. SARC‑F: A Simple Questionnaire to Rapidly Diagnose Sarcopenia. J Am Med Dir Assoc. 2013; 14(8): 531–2.
30. Ohtaka A, Aoki H, Nagata M, et al. Sarcopenia is a poor prognostic factor of castrationresistant prostate cancer treated with docetaxel therapy. Prostate Int. 2019; 7(1): 9–14.
31. Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin. 2005; 55(2): 74–108.
32. Ibrahim A, Scher N, Williams G, et al. Approval Summary for Zoledronic Acid for Treatment of Multiple Myeloma and Cancer Bone Metastases. Clin Cancer Res. 2003; 9(7): 2394–9.
33. Katolická J. Bisfosfonáty u urologických malignit. Onkologie. 2013: 7(1): 18–21.
34. Sharma A, Sinha RJ, Singh V, et al. Implications of the Fracture Risk Assessment Algorithm for the assessment and improvement of bone health in patients with prostate cancer: a comprehensive review. Türk Ürol DergisiTurkish J Urol. 2019; 45(4): 245–53.
35. Shahinian VB, Goodwin JS. Risk of Fracture after Androgen Deprivation for Prostate Cancer. N Engl J Med. 2005; 352(2): 154–64.
36. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. The Journal of Urology. 2002; 168(3): 1005–1007.
37. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal Therapy in Metastatic Hormone‑Sensitive Prostate Cancer. N Engl J Med. 2015; 373(8): 737–46.
38. Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal Therapy in Metastatic Hormone‑Sensitive Prostate Cancer: Long‑Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018; 36(11): 1080–7.
39. Gravis G, Boher JM, Chen YH, et al. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG‑AFU15 Studies. Eur Urol. 2018; 73(6): 847– 55.
40. Fizazi K, Tran N, Fein L, et al. Abiraterone plus Prednisone in Metastatic, Castration Sensitive Prostate Cancer. N Engl J Med. 2017; 377(4): 352–60.
41. Francini E, Gray KP, Xie W, et al. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). The Prostate. 2018; 78(12): 889–95.
Štítky
Paediatric urologist Nephrology UrologyČlánok vyšiel v časopise
Czech Urology
2023 Číslo 2
Najčítanejšie v tomto čísle
- Prognostic factors in metastatic prostate cancer
- 5th edition of the 2022 WHO classification of prostate cancer: changes and novelties in the "Blue Book"
- Early complications after radical cystectomy before implementation of the ERAS concept (Enhanced Recovery After Surgery)
- The results of percutaneous nephrostomy tube placement under ultrasound guidance